Compare ZLAB & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | PTCT |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | China | United States |
| Employees | N/A | 991 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 5.4B |
| IPO Year | 2017 | 2006 |
| Metric | ZLAB | PTCT |
|---|---|---|
| Price | $25.10 | $63.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 17 |
| Target Price | $49.60 | ★ $80.65 |
| AVG Volume (30 Days) | 766.5K | ★ 918.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $460,156,000.00 | $264,734,000.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $26.03 | $17.70 |
| P/E Ratio | ★ N/A | $69.20 |
| Revenue Growth | 15.33 | ★ 36.19 |
| 52 Week Low | $15.96 | $58.90 |
| 52 Week High | $34.72 | $90.87 |
| Indicator | ZLAB | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 35.34 |
| Support Level | $24.81 | $63.29 |
| Resistance Level | $25.28 | $68.93 |
| Average True Range (ATR) | 0.77 | 1.97 |
| MACD | -0.14 | -0.31 |
| Stochastic Oscillator | 41.43 | 24.18 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.